MedTrace Logo

Dual Therapy in HIV Patients in 4 Days a Week Versus 7 Days a Week

NCT04867083 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 440

Last updated 2021-11-08

No results posted yet for this study

Summary

The trial is an open-label, multicenter, prospective, randomized trial in 2 parallel groups, evaluating at W48 the non inferiority of antiretroviral dual therapy taken 4 consecutive days per week versus antiretroviral dual therapy 7/7 days per week in HIV-1 infected patients with controlled viral load under antiretroviral dual therapy.

Conditions

  • HIV Infections

Interventions

DRUG

ARV bitherapie

1. Dolutégravir 50mg / Lamivudine 300mg per day 2. Dolutégravir 50mg / Rilpivirine 25mg per day 3. Darunavir/r 800mg/100mg / Lamivudine 300mg per day

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • ANRS, Emerging Infectious Diseases

    lead OTHER_GOV

Principal Investigators

  • Roland LANDMAN · Hôpital BICHAT

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-21
Primary Completion
2023-07-31
Completion
2024-07-31

Countries

  • France
  • Martinique

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04867083 on ClinicalTrials.gov